European equities closed lower on Tuesday as investors remained cautious over the timing of the Fed's reduction of its stimulus program.» Read More
With the market at a 12-year low, it's a healthy exercise to try and find some good things in this world. Here are 5 things we bet you didn't think of...
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
If you’re looking for trading action look no farther than healthcare. There’s something happening in almost every corner of this sector.
The guys go behind the headlines and give you their take on the dismal economics numbers that capped off the worst January ever. But there are still places where you can make fast money.
With word today that Roche is going hostile and cutting the price of its bid for shares of Genentech, what should be the first questions on the minds of investors?
Amgen Inc., the world's largest biotechnology company, reported earnings of $1.12 per share on first-quarter revenues of $3.6 billion on Thursday, beating most Wall Street expectations on cost-cutting measures.
Standard and Poor's has just released the results of its twice-a-year stock screen, designed to find Warren Buffett-style stocks. The new list features several tech stocks, including Apple, as well as a number of names from Europe and Asia. But some key Buffett criteria aren't taken into account by the screen.
Swiss drug maker Novartis said Thursday its fourth-quarter profit fell sharply, mainly due to restructuring costs, but that it would increase returns to shareholders with a new buyback program and an increase to its dividend.
BioCryst Pharmaceuticals drew the short straw, er, needle. The biotech company says a majority of patients in a mid-stage clinical trial of its experimental seasonal and pandemic flu antiviral Peramivir got the drug using too short of an injection needle.
Some 270 people have contracted the H5N1 virus or avian flu, according to the World Health Organization, and 164 of them have died. It's the high death rate--greater than 50%--that has alarmed so many health officials. One drug that is on the market for patients is Tamiflu--made by Gildead Sciences. Sales of the drug have made a big turnaround over the last few years...
It looks like the Journal of the American Medical Association (JAMA) chose fractures as the theme of its new issue. One study shows that taking a popular osteoporosis drug for 5 years and then going off of it for 5 years carries a residual beneficial effect almost as if the patient stayed on the drug for all 10 years. Merck paid for the study of its #3-selling drug, Fosamax. The only exception was a 55% increased risk of fractures of the spine for those who stopped taking Fosamax. Doctors say that means...
Pfizer CEO Jeffrey Kindler expressed disappointment about the failure of the company's new cholesterol drug but said Pfizer plans to continue growing through strategic acquisitions.